Lymph node density in papillary thyroid carcinoma is a prognostic factor after adjusting for pathological stage
Metrics: PDF 1139 views | HTML 1619 views | ?
Hidenori Suzuki1, Yusuke Koide1, Nobuhiro Hanai1, Daisuke Nishikawa1, Shintaro Beppu1, Shinji Mikami2 and Yasuhisa Hasegawa1
1Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
2Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashihara, Japan
Hidenori Suzuki, email: [email protected]
Keywords: lymph node density; papillary thyroid carcinoma; eighth edition of the Union for International Cancer Control TNM Classification of Malignant Tumors; survival; multivariate
Received: March 14, 2018 Accepted: April 24, 2018 Published: June 01, 2018
We investigated the possible association between the lymph node density and survival outcomes in differentiated papillary thyroid carcinoma, and examined whether the lymph node density was a predictor in a multivariate analysis adjusted for the pathological stage in the eighth edition of the Union for International Cancer Control Tumor-Node Metastasis Classification of Malignant Tumors. A total of 543 patients with papillary thyroid carcinoma were enrolled. We performed restaging according to the eighth edition. The lymph node density was the ratio between number of positive lymph nodes and total number of excised lymph nodes. A log-rank test and Cox’s proportional hazards model were used for univariate and multivariate analysis with adjustment for the pathological stage in the eighth edition, respectively. In both the univariate and multivariate analyses of 150 patients with pN1bM0, the presence of a lymph node density of ≥ 0.3 with pN1b was significantly associated with shorter disease-specific survival. In both the univariate and multivariate analyses of all 543 patients, a lymph node density of ≥ 0.3 with pN1b were also significantly associated with shorter overall and disease-specific survival. In conclusion, these results suggest that the lymph node density can be used as a predictor for the survival outcomes after adjustment for the pathological stage in the eighth edition.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.